Posted on May 20, 2016 by Sitemaster
It appears that when it comes to the new data to be presented at ASCO this year, this will be the first time for several years that we don’t see some really groundbreaking new data from a large Phase III trial of some new form of therapy at one of the major meetings. But there is a lot of detail and a lot of information about new trials in development. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: endpoint, hypothesis, surrogate, validation | Leave a comment »
Posted on May 18, 2016 by Sitemaster
In a research study synthesis published in European Urology, Anthony D’Amico raises the hypothesis that androgen deprivation therapy (ADT) is most effective with Gleason pattern 4, but has lesser or no effect when prostate tumors include Gleason pattern 5. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: 5, Gleason, hypothesis, pattern | 7 Comments »
Posted on November 24, 2014 by Sitemaster
The “New” Prostate Cancer InfoLink has taken the position for quite a while that active surveillance could well be a highly appropriate management strategy for some men with a Gleason score of 3 + 4 = 7 at diagnosis (but far from all of them) — if they still met certain other criteria as good candidates for this form of management. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 3 + 4 = 7, active, Gleason, hypothesis, surveillance | 3 Comments »
Posted on September 16, 2014 by Sitemaster
For all of the past 30 years, it has been the accepted wisdom that starting a patient on medically induced androgen deprivation therapy (ADT, e.g., with leuproplide acetate/Lupron) during treatment of prostate cancer placed the patient at risk for an initial “flare” response that induced a short-term stimulus to serum testosterone levels and therefore to the development of any tumor. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: flare, hypothesis, reaction | 8 Comments »
Posted on January 17, 2014 by Sitemaster
There was an intriguing paper in the November 2013 issue of the journal Prostate suggesting that intermittent dosing with testosterone in between doses of androgen deprivation therapies may actually help men in the early stages of castration resistance to respond better to treatment over time. … READ MORE …
Filed under: Uncategorized | Tagged: boost, castration-resistance, CRPC, hypothesis, model, teststerone | 4 Comments »
Posted on December 8, 2012 by Sitemaster
In July 2010 we commented on an article in The Daily Mail that was based on data from a team of Korean researchers who’d been busily measuring the lengths of the second and fourth fingers of the right hands of men presenting at their urology clinic. They were convinced that there was a correlation between relative finger length and risk for prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: finger, grade, hypothesis, length, risk | 3 Comments »
Posted on August 16, 2011 by Sitemaster
For those who like to know what is happening out on the farther reaches of cancer research, there is an interesting article by George Johnson in today’s New York Times. … READ MORE …
Filed under: Uncategorized | Tagged: cancer, development, hypothesis | Leave a comment »
Posted on April 23, 2010 by Sitemaster
In February this year Efstathiou and Logothetis published an article in Clinical Cancer Research stating that the traditional model of cancer drug development — seeking agents that had some activity in very later stages of the cancer and then “working backwards” to explore the effects of these agents earlier in the disease — had been ineffective in prostate cancer. … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: development, drug, hypothesis, model | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 